

# 42 - References

## References

### Bipolar disorder CHAPTER 2 References

1. ECNP. Neuroscience-based nomenclature (NbN). 2024; <https://www.ecnp.eu/research--innovation/nomenclature>.
2. Cipriani A, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. *Lancet* 2011; 378:1306-1315.
3. Goodwin GM, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. *J Psychopharmacol* 2016; 30:495-553.
4. Chou JC, et al. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. *J Clin Psychopharmacol* 1999; 19:500-505.
5. Small JG, et al. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. *Am J Psychiatry* 1975; 132:1315-1317.
6. Soares JC, et al. Adjunctive antipsychotic use in bipolar patients: an open 6-month prospective study following an acute episode. *J Affect Disord* 1999; 56:1-8.
7. Keck PE, Jr, et al. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. *J Clin Psychiatry* 1998; 59 Suppl 6:74-81.
8. Tohen M, et al. Antipsychotic agents and bipolar disorder. *J Clin Psychiatry* 1998; 59 Suppl 1:38-48.
9. Zarate CA, Jr, et al. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. *Am J Psychiatry* 2004; 161:169-171.
10. Gigante AD, et al. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. *CNS Drugs* 2012; 26:403-420.
11. Goikolea JM, et al. Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. *J Affect Disord* 2013; 144:191-198.
12. Yildiz A, et al. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. *Psychol Med* 2015; 45:299-317.
13. Kishi T, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. *Mol Psychiatry* 2022; 27:1136-1144.
14. Baldessarini RJ, et al. Pharmacological treatment of adult bipolar disorder. *Mol Psychiatry* 2019; 24:198-217.

15. Yu CL, et al. Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia. *BMJ Ment Health* 2023; 26:e300546.
16. Ogawa Y, et al. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. *CNS Drugs* 2014; 28:989–1003.
17. Ashok AH, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. *Mol Psychiatry* 2017; 22:666–679.
18. Jauhar S, et al. A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. *JAMA Psychiatry* 2017; 74:1206–1213.
19. Taylor DM, et al. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. *Acta Psychiatr Scand* 2014; 130:452--469.
20. Yildiz A, et al. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. *Lancet Psychiatry* 2023; 10:693–705.
21. Kadakia A, et al. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. *BMC Psychiatry* 2021; 21:249.
22. Martins-Correia J, et al. Cariprazine in the acute treatment of unipolar and bipolar depression: a systematic review and meta-analysis. *J Affect Disord* 2024; 362:297–307.
23. Taylor MJ. Bipolar treatment efficacy. *Lancet Psychiatry* 2014; 1:418.
24. Miura T, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. *Lancet Psychiatry* 2014; 1:351–359.
25. McIntyre RS, et al. Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder. *Bipolar Disord* 2024; 26:442–453.
26. Sachs G, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. *J Psychopharmacol* 2006; 20:536–546.
27. Keck PE, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium- controlled study. *J Affect Disord* 2009; 112:36–49.
28. Young AH, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. *Br J Psychiatry* 2009; 194:40–48.
29. Vieta E, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/ lithium monotherapy: a placebo-controlled study. *Am J Psychiatry* 2008; 165:1316–1325.
30. Keck PE, Jr, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. *J Clin Psychiatry* 2007; 68:1480–1491.
31. Vieta E, et al. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. *Curr Med Res Opin* 2010; 26:1485–1496.
32. Shafti SS. Aripiprazole versus lithium in management of acute mania: a randomized clinical trial. *East Asian Arch Psychiatry* 2018; 28:80–84.
33. Brown R, et al. Aripiprazole alone or in combination for acute mania. *Cochrane Database Syst Rev* 2013; 12:CD005000.

34. Calabrese JR, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. *J Clin Psychiatry* 2017; 78:324–331.

304 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 2 35. McIntyre RS, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. *J Affect Disord* 2010; 122:27–38. 36. McIntyre RS, et al. Asenapine versus olanzapine in acute mania: a double-blind extension study. *Bipolar Disord* 2009; 11:815–826. 37. McIntyre RS, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. *J Affect Disord* 2010; 126:358–365. 38. Szegedi A, et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. *Am J Psychiatry* 2018; 175:71–79. 39. Pillinger T, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. *Lancet Psychiatry* 2020; 7:64–77. 40. McIntyre RS, et al. Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials. *J Affect Disord* 2019; 257:600–606. 41. Zarate CA, Jr, et al. Clozapine in severe mood disorders. *J Clin Psychiatry* 1995; 56:411–417. 42. Li XB, et al. Clozapine for treatment-resistant bipolar disorder: a systematic review. *Bipolar Disord* 2015; 17:235–247. 43. Loo LWJ, et al. Clozapine use for bipolar disorder: an Asian Psychotropic Prescription Patterns Consortium Study. *J Clin Psychopharmacol* 2023; 43:278–282. 44. Loebel A, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry* 2014; 171:160–168. 45. Loebel A, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. *Am J Psychiatry* 2014; 171:169–177. 46. Tohen M, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. *Am J Psychiatry* 1999; 156:702–709. 47. Tohen M, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. *Arch Gen Psychiatry* 2000; 57:841–849. 48. Tohen M, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. *Arch Gen Psychiatry* 2002; 59:62–69. 49. Tohen M, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. *Br J Psychiatry* 2004; 184:337–345. 50. Tohen M, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. *Br J Psychiatry* 2008; 192:135–143. 51. Sanger TM, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. *J Clin Psychiatry* 2001; 62:273–281. 52. Vieta E, et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. *J Clin Psychopharmacol* 2001; 21:469–473. 53. Tohen M, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. *Am J Psychiatry* 2005; 162:1281–1290. 54. McKnight RF, et al. Lithium for acute mania. *Cochrane Database Syst Rev* 2019; 6:CD004048. 55. Corrao MM, et al. Olanzapine/samidorphan: a new combination treatment for schizophrenia and bipolar I disorder intended to reduce weight gain. *CNS Drugs* 2022; 36:605–616. 56. Faden J, et al. Olanzapine--samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used? *Expert Rev Neurother* 2022; 22:365–376. 57. Ghaemi SN, et al. The use of quetiapine for treatment-resistant bipolar disorder: a case series. *Ann Clin Psychiatry* 1999; 11:137–140. 58. Sachs G, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. *Bipolar Disord* 2004; 6:213–223. 59.

Altamura AC, et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open label study. *J Affect Disord* 2003; 76:267–271. 60. Young AH, et al. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. *World J Biol Psychiatry* 2014; 15:96–112. 61. Segal J, et al. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. *Clin Neuropharmacol* 1998; 21:176–180. 62. Sachs GS, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo- controlled comparison of efficacy and safety. *Am J Psychiatry* 2002; 159:1146–1154. 63. Vieta E, et al. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. *J Affect Disord* 2002; 72:15–19. 64. Quiroz JA, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. *Biol Psychiatry* 2010; 68:156–162. 65. Taylor DM, et al. Paliperidone palmitate: factors predicting continuation with treatment at 2 years. *Eur Neuropsychopharmacol* 2016; 26:2011--2017. 66. Vieta E, et al. An open-label study of amisulpride in the treatment of mania. *J Clin Psychiatry* 2005; 66:575–578. 67. Vieta E, et al. Ziprasidone in the treatment of acute mania: a 12--week, placebo-controlled, haloperidol-referenced study. *J Psychopharmacol* 2010; 24:547–558. 68. Singh V, et al. An open trial of iloperidone for mixed episodes in bipolar disorder. *J Clin Psychopharmacol* 2017; 37:615–619. 69. McIntyre RS, et al. The efficacy of lumateperone in patients with bipolar depression with mixed features. *J Clin Psychiatry* 2023; 84:22m14739. 70. Calabrese JR, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. *Am J Psychiatry* 2021; 178:1098–1106.

---

Revision #1

Created 2026-01-04 20:14:26 UTC by Omar Ayman

Updated 2026-01-04 20:14:26 UTC by Omar Ayman